|
Rheumatoid Arthritis
|
0.130 |
GeneticVariation
|
disease |
BEFREE |
Recently, apoM polymorphisms have been related with RA susceptibility.
|
23190940 |
2013 |
|
Rheumatoid Arthritis
|
0.130 |
GeneticVariation
|
disease |
BEFREE |
These findings suggest that the functional single-nucleotide polymorphism APOM rs805297 G/T variant allele was associated with RA risk.
|
23660425 |
2014 |
|
Rheumatoid Arthritis
|
0.130 |
GeneticVariation
|
disease |
BEFREE |
Through GWAS, we identified a novel SNP associated with RA at the APOM gene in the MHC class III region on 6p21.33 (rs805297, odds ratio (OR) = 2.28, P = 5.20 × 10-7).
|
21844665 |
2011 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.130 |
Biomarker
|
disease |
BEFREE |
There were no differences in plasma levels of apoM and S1P between controls and T1D patients, but the apoM/S1P complexes were shifted from dense to light HDL particles in T1D.
|
28385702 |
2017 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.130 |
GeneticVariation
|
disease |
BEFREE |
In the present study, we investigate the potential association between the ApoM promoter polymorphisms and type 1 diabetes.
|
19007767 |
2009 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.130 |
Biomarker
|
disease |
BEFREE |
Apolipoprotein M can discriminate HNF1A-MODY from Type 1 diabetes.
|
23157689 |
2013 |
|
Lupus Erythematosus, Systemic
|
0.120 |
Biomarker
|
disease |
BEFREE |
Plasma concentrations of apoM were measured by ELISA in two patient groups with systemic lupus erythematosus (SLE) and in 79 healthy control individuals.
|
31046824 |
2019 |
|
Lupus Erythematosus, Systemic
|
0.120 |
Biomarker
|
disease |
BEFREE |
No association between APOM and SLE susceptibility was detected in our Han Chinese cohort.
|
28476116 |
2017 |
|
Malignant neoplasm of lung
|
0.110 |
Biomarker
|
disease |
BEFREE |
Apolipoprotein M promotes proliferation and invasion in non-small cell lung cancers via upregulating S1PR1 and activating the ERK1/2 and PI3K/AKT signaling pathways.
|
29750961 |
2018 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Overexpression of HDL-associated apolipoprotein M (apoM) protects mice against atherosclerosis through a not yet clarified mechanism.
|
22204862 |
2012 |
|
Arteriosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Apolipoprotein M is a recently described HDL-associated apoprotein expressed mainly in the liver and kidney with protective effects against atherosclerosis.
|
18054359 |
2008 |
|
Arteriosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The axis of apolipoprotein M (apoM) and sphingosine-1-phosphate (S1P) is of importance to plasma lipid levels, endothelial function, and development of atherosclerosis.
|
30433864 |
2019 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recent studies have suggested that apolipoprotein M (ApoM), a carrier protein for S1P, modulates the biological properties of S1P in the pathogenesis of atherosclerosis.
|
29301231 |
2017 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In spite of the important role of Apolipoprotein-M (ApoM) and Sphingosine-1-Phosphate (S1P) played in atherosclerosis (AS), there was few related research reporting ApoM and S1P complex (ApoM-S1P) on biological activities of human umbilical vein endothelial cells (HUVECs).
|
31791242 |
2019 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Apolipoprotein M (apoM) is present predominantly in high-density lipoprotein (HDL) in human plasma, thus possibly involved in the regulation of HDL metabolism and the process of atherosclerosis.
|
21816233 |
2011 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Effects of apolipoprotein M in uremic atherosclerosis.
|
28866363 |
2017 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Effect of apolipoprotein M on high density lipoprotein metabolism and atherosclerosis in low density lipoprotein receptor knock-out mice.
|
18006500 |
2008 |
|
Arteriosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In genetically modified mice, however, changes in plasma apoM concentration caused quantitative and qualitative changes in HDLs, and overexpression of the apoM gene reduced atherosclerosis.
|
19200746 |
2009 |
|
Arteriosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In accordance with this idea, hepatic overexpression of apolipoprotein M with an adenovirus in low-density lipoprotein-receptor deficient mice led to an approximately 70% reduction of atherosclerosis.
|
16680035 |
2006 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The HDL associated apolipoprotein M (apoM) protects against experimental atherosclerosis but the mechanism is unknown.ApoM increases prebeta-HDL formation.
|
24046869 |
2013 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Opposing effects of apolipoprotein m on catabolism of apolipoprotein B-containing lipoproteins and atherosclerosis.
|
20360257 |
2010 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
To clarify what role apoM plays in atherosclerosis, we used oxidized low-density lipoprotein (ox-LDL) to induce an inflammatory model of atherosclerosis.
|
30377890 |
2019 |
|
Atherosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In genetically modified mice, however, changes in plasma apoM concentration caused quantitative and qualitative changes in HDLs, and overexpression of the apoM gene reduced atherosclerosis.
|
19200746 |
2009 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The HDL associated apolipoprotein M (apoM) protects against experimental atherosclerosis but the mechanism is unknown.ApoM increases prebeta-HDL formation.
|
24046869 |
2013 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recent studies have suggested that apolipoprotein M (ApoM), a carrier protein for S1P, modulates the biological properties of S1P in the pathogenesis of atherosclerosis.
|
29301231 |
2017 |